| Bioactivity | EP1013 (F1013) is a broad-spectrum caspase selective inhibitor, used in the research of type 1 diabetes[1]. | ||||||||||||
| In Vivo | EP1013 (1, 3, 10 mg/kg) significantly improves marginal islet mass function. Two animals in the 10 mg/kg EP1013 treatment group exhibit primary islet graft nonfunction, but the diabetes reversalrate for this group is not significantly different from the 3 mg/kg EP1013, 1 mg/kg EP1013, or 10 mg/kg zVAD groups. EP1013 therapy enhances functional syngeneic islet mass and promotes longevity of islet graft function[1]. | ||||||||||||
| Name | EP1013 | ||||||||||||
| CAS | 223568-55-6 | ||||||||||||
| Formula | C18H23FN2O6 | ||||||||||||
| Molar Mass | 382.38 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Emamaullee JA, et al. The caspase selective inhibitor EP1013 augments human islet graft function and longevity in marginal mass islet transplantation in mice. Diabetes. 2008 Jun;57(6):1556-66. |